CERT - Certara, Inc.
LOS ANGELES, May 24, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Certara, Inc. ("Certara" or "the Company") (NASDAQ: CERT) for violations of the securities laws.
LOS ANGELES, May 24, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Certara, Inc. (“Certara” or “the Company”) (NASDAQ: CERT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that services re.
Certara, Inc. (CERT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.
RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Certara (CERT) To Contact Him Directly To Discuss Their Options
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On May 11, 2026, Certara reported its first quarter 2026 financial results. Certara disclosed that service.
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Certara, Inc. (NASDAQ: CERT). The investigation focuses on Certara's executive officers and whether investor losses may be recovered under federal securities laws.
Certara, Inc. (CERT) Q1 2026 Earnings Call Transcript
Certara NASDAQ: CERT reported first-quarter 2026 revenue of $106.9 million, up 1% from the prior-year period, as stronger software performance offset softer services results and the company outlined a strategic reset under Chief Executive Officer Jon Resnick.
Certara, Inc. (CERT) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.14 per share a year ago.
Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business
LAVAL, Québec & RADNOR, Pa.--(BUSINESS WIRE)-- #Altasciences--Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals.
Certara Inc. (NASDAQ:CERT) shares are up 2.34% on Wednesday as the company announced it has entered into a definitive agreement to sell its Regulatory and Medical Writing business.
SOUTHBOROUGH, Mass.--(BUSINESS WIRE)-- #Biotech--Veristat (the “Company”), a science-first full-service CRO and consultancy that advances complex therapies through the drug development lifecycle to regulatory submission, announced today its intended acquisition of Certara's Regulatory and Medical Writing business. The team that will join Veristat is known for its white-glove advisory services and deep expertise authoring clinical and non-clinical documents throughout the drug development lifecycle. The ac.